New York City-based digital mental health company Minded Inc. has raised $25 million in seed funding, marking a major milestone in its mission to increase access to psychiatric care through technology. The investment will drive Minded’s telepsychiatry platform expansion across the United States, enabling the company to reach more patients and offer an expanded suite of behavioral health treatments. Since its founding in 2021, Minded has been dedicated to breaking down barriers that prevent many Americans from accessing quality mental health care, and this fresh infusion of capital will help realize that vision on a larger scale.
Currently, Minded’s services are available in California, Florida, Illinois, New York, New Jersey, Pennsylvania, and Texas. The company’s initial focus on these states has allowed it to refine its platform and care model, but the new funding will accelerate Minded’s telepsychiatry platform expansion into many additional states. This geographic growth aims to meet the rising demand for mental health services nationwide, particularly in underserved areas where access to psychiatric providers is limited or nonexistent.
Alongside expanding its geographic reach, Minded is also broadening the range of conditions it treats. Planned additions include therapies for mood disorders such as depression and anxiety, treatments for attention-deficit disorders, and pioneering psychedelic-assisted therapies that show promise in clinical research. Furthermore, Minded will introduce genetic testing services to enhance medication management. This cutting-edge approach uses patients’ genetic information to guide more accurate prescribing decisions, potentially improving treatment outcomes and reducing side effects.
The platform itself is designed for convenience and accessibility. Patients start with a free online mental health assessment to identify their needs. From there, they can schedule video visits with board-certified psychiatrists or psychiatric nurse practitioners. Prescriptions can then be filled at local pharmacies or delivered directly to patients’ homes—removing the logistical hurdles that often delay treatment. This user-centric model is a key driver behind Minded’s telepsychiatry platform expansion, as it allows more individuals to receive timely, expert care without the stigma or travel barriers typically associated with in-person psychiatric visits.
David Ronick, co-founder and CEO of Minded, describes the company’s overarching goal: “Minded is on a mission to make it easy for millions of people to be just a few days and a Zoom call away from speaking with a caring, compassionate expert.” This vision has attracted backing from notable venture capital firms including Streamlined Ventures, Link Ventures, and The Tiger Fund, alongside experienced founders from companies like Care.com and RXBAR. This broad investor confidence is a strong endorsement of Minded’s approach and its ability to execute on ambitious telepsychiatry platform expansion plans.
Addressing the Mental Health Crisis with Technology
The timing of Minded’s growth coincides with a critical mental health crisis in the United States. Data from the Centers for Disease Control and Prevention show that during the COVID-19 pandemic, anxiety rates tripled and depression rates quadrupled compared to pre-pandemic levels. Despite this soaring demand, the supply of psychiatric providers has not kept pace, leaving many Americans struggling to find timely, effective care. Minded’s platform leverages technology to help close this widening gap.
A major enabler of this surge in digital mental health innovation is regulatory flexibility introduced during the pandemic. Specifically, the Ryan Haight Act, which traditionally limits the ability of providers to prescribe controlled substances via telemedicine without an initial in-person exam, was temporarily relaxed under the federal public health emergency declaration. This exemption has been instrumental in facilitating Minded’s telepsychiatry platform expansion, allowing the company to prescribe medications such as Xanax, Ativan, Ambien, and Lunesta remotely. However, Minded currently does not prescribe ADHD medications under this model.
Investor Confidence and Industry Momentum
This regulatory landscape has spurred investor enthusiasm across the sector, with other digital psychiatry companies raising substantial funding rounds. For instance, Cerebral Health closed a $300 million Series C round, reaching a valuation near $5 billion, while Ophelia Health secured $50 million in Series B funding focused on opioid use disorder treatments. Minded’s telepsychiatry platform expansion positions it well to compete and collaborate in this fast-growing market.
Future Policy Reforms and Personalized Psychiatry
Looking to the future, bipartisan mental health legislation expected to move through Congress this summer may include permanent reforms to telehealth prescribing rules, potentially making the Ryan Haight Act exemptions permanent or introducing new frameworks. The Biden administration has expressed support for these changes as part of a broader strategy to improve behavioral health access nationwide. If successful, these reforms would further accelerate Minded’s telepsychiatry platform expansion, enabling even greater patient reach and service diversity.
Beyond regulatory and funding factors, Minded’s upcoming integration of genetic testing represents an important step toward personalized psychiatry. Genetic testing can reveal how individual patients metabolize certain medications, allowing clinicians to tailor prescriptions for maximum effectiveness and minimal side effects. Coupled with emerging psychedelic therapies—such as psilocybin-assisted treatment—this holistic expansion reflects Minded’s commitment to incorporating the latest science into digital mental health care.
Conclusion
In summary, Minded Inc.’s recent $25 million seed funding marks a pivotal moment for its telepsychiatry platform expansion and the future of accessible mental health care. By scaling its services to new states, broadening its treatment options, and embracing personalized medicine innovations, Minded aims to transform how millions of people engage with psychiatric care. As mental health challenges continue to grow nationwide, technology-driven solutions like Minded’s are poised to play an essential role in closing the treatment gap and improving patient outcomes.
